You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
譽衡藥業(002437.SZ)上修業績預吿:半年度預盈9000萬-11000萬元
格隆匯 07-14 16:17

格隆匯7月14日丨譽衡藥業(002437.SZ)發佈2021年半年度業績預吿修正公吿,此前披露的《2021年第一季度報吿全文》中預計:2021年半年度歸屬於上市公司股東的淨利潤為盈利4000萬元-5000萬元,較上年同期下降92.53%-94.02%。

修正後,預計2021年半年度歸屬於上市公司股東的淨利潤9000萬元-11000萬元,同比下降83.56%-86.55%。業績預吿修正的原因如下:

1根據財政部新修訂的《企業會計準則第22——金融工具確認和計量》,公司持有的WuXi Healthcare Ventures II, L.P. (“毓承資本”)權投資確認為以公允價值計量且其變動計入當期損益的金融資產報吿期內,公司持有毓承資本的股權投資產生公允價值變動損益約4600萬元,對業績產生一定影響此部分收益為非經常性損益。

2、剔除上年同期出售澳諾製藥投資收益報吿期持有毓承資本金融資公允價值變動損益後,報吿期公司業績較上年同期有所增長,主要是因為新冠肺炎疫情得到有效控制,公司大部分產品銷售較上年同期有所增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account